|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTTNBP2NL |
Gene summary for CTTNBP2NL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTTNBP2NL | Gene ID | 55917 |
| Gene name | CTTNBP2 N-terminal like | |
| Gene Alias | CTTNBP2NL | |
| Cytomap | 1p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R0C7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55917 | CTTNBP2NL | HTA11_347_2000001011 | Human | Colorectum | AD | 4.67e-16 | 7.53e-01 | -0.1954 |
| 55917 | CTTNBP2NL | HTA11_411_2000001011 | Human | Colorectum | SER | 4.01e-04 | 7.76e-01 | -0.2602 |
| 55917 | CTTNBP2NL | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.78e-06 | -3.49e-01 | 0.3005 |
| 55917 | CTTNBP2NL | A001-C-207 | Human | Colorectum | FAP | 9.11e-03 | -1.99e-01 | 0.1278 |
| 55917 | CTTNBP2NL | A015-C-203 | Human | Colorectum | FAP | 1.89e-23 | -3.37e-01 | -0.1294 |
| 55917 | CTTNBP2NL | A015-C-204 | Human | Colorectum | FAP | 5.30e-06 | -3.89e-01 | -0.0228 |
| 55917 | CTTNBP2NL | A014-C-040 | Human | Colorectum | FAP | 1.56e-02 | -2.11e-01 | -0.1184 |
| 55917 | CTTNBP2NL | A002-C-201 | Human | Colorectum | FAP | 1.68e-11 | -3.41e-01 | 0.0324 |
| 55917 | CTTNBP2NL | A002-C-203 | Human | Colorectum | FAP | 1.24e-03 | -1.78e-01 | 0.2786 |
| 55917 | CTTNBP2NL | A001-C-108 | Human | Colorectum | FAP | 1.15e-12 | -2.10e-01 | -0.0272 |
| 55917 | CTTNBP2NL | A002-C-205 | Human | Colorectum | FAP | 1.05e-17 | -6.05e-02 | -0.1236 |
| 55917 | CTTNBP2NL | A015-C-005 | Human | Colorectum | FAP | 2.86e-02 | -2.11e-01 | -0.0336 |
| 55917 | CTTNBP2NL | A015-C-006 | Human | Colorectum | FAP | 8.85e-12 | -3.55e-01 | -0.0994 |
| 55917 | CTTNBP2NL | A015-C-106 | Human | Colorectum | FAP | 4.57e-12 | -2.69e-01 | -0.0511 |
| 55917 | CTTNBP2NL | A002-C-114 | Human | Colorectum | FAP | 6.97e-16 | -8.67e-02 | -0.1561 |
| 55917 | CTTNBP2NL | A015-C-104 | Human | Colorectum | FAP | 5.03e-25 | -2.12e-01 | -0.1899 |
| 55917 | CTTNBP2NL | A001-C-014 | Human | Colorectum | FAP | 5.49e-10 | -2.42e-01 | 0.0135 |
| 55917 | CTTNBP2NL | A002-C-016 | Human | Colorectum | FAP | 4.68e-18 | -2.92e-01 | 0.0521 |
| 55917 | CTTNBP2NL | A015-C-002 | Human | Colorectum | FAP | 1.10e-09 | -4.17e-01 | -0.0763 |
| 55917 | CTTNBP2NL | A001-C-203 | Human | Colorectum | FAP | 3.12e-09 | -1.14e-01 | -0.0481 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:00064701 | Colorectum | SER | protein dephosphorylation | 65/2897 | 281/18723 | 4.44e-04 | 6.51e-03 | 65 |
| GO:0051051 | Colorectum | SER | negative regulation of transport | 98/2897 | 470/18723 | 1.01e-03 | 1.19e-02 | 98 |
| GO:00163111 | Colorectum | SER | dephosphorylation | 86/2897 | 417/18723 | 2.73e-03 | 2.46e-02 | 86 |
| GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
| GO:00064702 | Colorectum | MSS | protein dephosphorylation | 73/3467 | 281/18723 | 1.15e-03 | 1.12e-02 | 73 |
| GO:00163112 | Colorectum | MSS | dephosphorylation | 101/3467 | 417/18723 | 1.98e-03 | 1.70e-02 | 101 |
| GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
| GO:00510511 | Colorectum | MSS | negative regulation of transport | 110/3467 | 470/18723 | 4.20e-03 | 3.04e-02 | 110 |
| GO:00163113 | Colorectum | FAP | dephosphorylation | 95/2622 | 417/18723 | 7.07e-07 | 3.32e-05 | 95 |
| GO:00064704 | Colorectum | FAP | protein dephosphorylation | 69/2622 | 281/18723 | 1.47e-06 | 6.39e-05 | 69 |
| GO:00324092 | Colorectum | FAP | regulation of transporter activity | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
| GO:00510512 | Colorectum | FAP | negative regulation of transport | 91/2622 | 470/18723 | 7.09e-04 | 7.64e-03 | 91 |
| GO:00163114 | Colorectum | CRC | dephosphorylation | 79/2078 | 417/18723 | 1.27e-06 | 7.21e-05 | 79 |
| GO:00064705 | Colorectum | CRC | protein dephosphorylation | 57/2078 | 281/18723 | 4.49e-06 | 1.87e-04 | 57 |
| GO:00324093 | Colorectum | CRC | regulation of transporter activity | 59/2078 | 310/18723 | 2.34e-05 | 6.65e-04 | 59 |
| GO:00510513 | Colorectum | CRC | negative regulation of transport | 71/2078 | 470/18723 | 4.33e-03 | 3.47e-02 | 71 |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTTNBP2NL | SNV | Missense_Mutation | novel | c.636C>A | p.Ser212Arg | p.S212R | Q9P2B4 | protein_coding | tolerated(0.19) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTTNBP2NL | SNV | Missense_Mutation | c.1364N>A | p.Ile455Asn | p.I455N | Q9P2B4 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CTTNBP2NL | SNV | Missense_Mutation | c.1807N>T | p.His603Tyr | p.H603Y | Q9P2B4 | protein_coding | tolerated(0.27) | benign(0.099) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CTTNBP2NL | SNV | Missense_Mutation | c.1894G>C | p.Glu632Gln | p.E632Q | Q9P2B4 | protein_coding | deleterious(0.02) | benign(0.287) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| CTTNBP2NL | SNV | Missense_Mutation | novel | c.1768N>C | p.Thr590Pro | p.T590P | Q9P2B4 | protein_coding | deleterious(0) | benign(0.091) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| CTTNBP2NL | SNV | Missense_Mutation | rs754747435 | c.775N>T | p.Arg259Trp | p.R259W | Q9P2B4 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
| CTTNBP2NL | SNV | Missense_Mutation | c.1723N>C | p.Glu575Gln | p.E575Q | Q9P2B4 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| CTTNBP2NL | insertion | Nonsense_Mutation | novel | c.1053_1054insATTACATGGTCATTGTGCTTACAATGAAAAACAGTTTTC | p.His351_Cys352insIleThrTrpSerLeuCysLeuGlnTerLysThrValPhe | p.H351_C352insITWSLCLQ*KTVF | Q9P2B4 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CTTNBP2NL | insertion | Nonsense_Mutation | novel | c.1681_1682insTCGCTTGAACCCAGAAGGCGGAGGTTGCAGTGAG | p.Pro561LeufsTer3 | p.P561Lfs*3 | Q9P2B4 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| CTTNBP2NL | insertion | Nonsense_Mutation | novel | c.1322_1323insCACCTCTTATCTAACTATATAAAAATGTATATTATT | p.Ser441_Ala442insThrSerTyrLeuThrIleTerLysCysIleLeuLeu | p.S441_A442insTSYLTI*KCILL | Q9P2B4 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |